Literature DB >> 14764827

Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells.

Nicoletta Fortunati1, Maria G Catalano, Katia Arena, Enrico Brignardello, Alessandro Piovesan, Giuseppe Boccuzzi.   

Abstract

In poorly differentiated thyroid cancer, molecular characteristics are reported to be lost such as to cause insensitivity of the tumor to radiometabolic therapy. Considerable work is in progress to identify compounds that redifferentiate thyroid cancer cells. The present study evaluates the action of valproic acid, a potent anticonvulsant recently reported to inhibit histone deaceytlase, on cultured thyroid cancer cells. N-PA (poorly differentiated) and ARO (anaplastic) cells were treated with increasing valproic acid concentrations.; expression of mRNA and cell localization pattern for the Na+/I- symporter (NIS), as well as 125I uptake, were evaluated before and after treatment. Valproic acid induced NIS gene expression, NIS membrane localization and iodide accumulation in N-PA cells; it was effective at clinically-safe doses in the therapeutic range. In ARO cells, only induction of NIS mRNA was observed, and was not followed by any change in iodide uptake. Valproic acid is thus effective at restoring the ability of N-PA cells to accumulate iodide and its use in clinical trials may be recommended.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764827     DOI: 10.1210/jc.2003-031407

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

1.  A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.

Authors:  Naris Nilubol; Roxanne Merkel; Lily Yang; Dhaval Patel; James C Reynolds; Samira M Sadowski; Vladimir Neychev; Electron Kebebew
Journal:  Clin Endocrinol (Oxf)       Date:  2016-09-08       Impact factor: 3.478

Review 2.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

Review 3.  Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.

Authors:  Pamela Jo Harris; Keith C Bible
Journal:  Expert Opin Investig Drugs       Date:  2011-10       Impact factor: 6.206

Review 4.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

5.  5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.

Authors:  Geneviève Dom; Vanessa Chico Galdo; Maxime Tarabichi; Gil Tomás; Aline Hébrant; Guy Andry; Viviane De Martelar; Frédérick Libert; Emmanuelle Leteurtre; Jacques E Dumont; Carine Maenhaut; Wilma C G van Staveren
Journal:  Thyroid       Date:  2013-03       Impact factor: 6.568

6.  Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275.

Authors:  Annette Altmann; Michael Eisenhut; Ulrike Bauder-Wüst; Annette Markert; Vasileios Askoxylakis; Holger Hess-Stumpp; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-03       Impact factor: 9.236

Review 7.  Alternative medical treatment for radioiodine-refractory thyroid cancers.

Authors:  Jin Chul Paeng; Keon Wook Kang; Do Joon Park; So Won Oh; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2011-09-17

8.  The Effect of Tanespimycin (17-AAG) on Radioiodine Accumulation in Sodium-Iodide Symporter Expressing Cells.

Authors:  Kyoung Hyun Yu; Hyewon Youn; Myung Geun Song; Dong Soo Lee; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2012-08-15

9.  Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.

Authors:  S Jang; X-M Yu; S Odorico; M Clark; R Jaskula-Sztul; C M Schienebeck; K R Kupcho; A D Harrison; G N Winston-McPherson; W Tang; H Chen
Journal:  Cancer Gene Ther       Date:  2015-08-07       Impact factor: 5.987

10.  Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth.

Authors:  Xiao-Min Yu; Renata Jaskula-Sztul; Kamal Ahmed; April D Harrison; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Mol Cancer Ther       Date:  2013-04-17       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.